Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
13%
Ph phase_2
4
50%
Ph phase_1
3
38%

Phase Distribution

3

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 24 (50.0%)
Phase 31 (12.5%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_1

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

NCT01762462
completedphase_1

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

NCT01585623
completedphase_2

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

NCT01523171
completedphase_3

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

NCT01437787
completedphase_2

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

NCT01420770
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01762462Phase 1

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

Completed
NCT01585623Phase 1

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

Completed
NCT01523171Phase 2

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

Completed
NCT01437787Phase 3

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

Completed
NCT01420770Phase 2

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

Completed
NCT01763190Phase 1

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

Completed
NCT01420783Phase 2

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Completed
NCT01692366Phase 2

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8